Enantia, selected by Neogenius as preferred partner

Set up on the basis of a strategic alliance between four pharmaceutical companies (Almirall, Esteve, Palau Pharma and Proteomika), the NEOGENIUS project will run for four years with a total budget of 15.4 million euros with the objective to discover and develop new painkilling medicines for patients suffering from osteoarthritis.

Enantia has been selected as custom synthesis provider to support the drug discovery activities of the consortium.

The history of NEOGENIUS as a consortium can be traced back to the GENIUS PHARMA project, a CENIT project approved in the first call for this programme in 2006 in which, in adition to Almirall, Esteve and Palau Pharma, other technological companies, among them, Enantia, also participated. GENIUS PHARMA attained its objective of consolidating different SMEs and PROs in Spain as technological platforms in different pharmaceutical research settings. In fact, NEOGENIUS’s external collaborations have been established with platforms from GENIUS PHARMA, which will provide this process with a high degree of inter-regionality and multidisciplinarity.

(May 18th, 2010)